Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25071645 | 0.86 | TSHR (0.59) | ALDH1A1HPGDTSHRHSD17B10CHRNB2 | |
| SCHEMBL9516370 | 0.85 | ALDH1A1 (0.52) | ALDH1A1HPGDTSHRHSD17B10CHRNB2 | |
| SCHEMBL18470038 | 0.84 | ALDH1A1 (0.57) | ALDH1A1HPGDTSHRHSD17B10CHRNB2 | |
| SCHEMBL15948527 | 0.82 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRHSD17B10LMNA | |
| SCHEMBL15948654 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HPGDTSHRHSD17B10LMNA | |
| SCHEMBL13901839 | 0.79 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10CHRNB2CHRNB4 | |
| SCHEMBL19287907 | 0.79 | ALDH1A1 (0.42) | ALDH1A1HPGDTSHRHSD17B10LMNA | |
| SCHEMBL16137273 | 0.79 | ALDH1A1 (0.57) | ALDH1A1HPGDTSHRHSD17B10LMNA | |
| SCHEMBL1106823 | 0.77 | CYP2D6 (0.46) | ALDH1A1HPGDHSD17B10CHRNB2CHRNB4 | |
| SCHEMBL8613878 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HPGDTSHRHSD17B10CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255129-B1 | THIOL-CARBOXYLIC ADDUCTS AS LUBRICATING ADDITIVES | LUBRIZOL CORP (US) | 2024-01-24 | — | — | EP | disclosed |
| US-10961481-B2 | Thiol-carboxylic adducts as lubricating additives | THE LUBRIZOL CORPORATION (US) | 2021-03-30 | — | — | US | disclosed |
| EP-2953457-B1 | ERK INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2020-04-08 | — | — | EP | disclosed |
| US-10029020-B2 | Fullerene compositions | UNIVERSITEIT GENT (BE) | 2018-07-24 | — | — | US | disclosed |
| US-20180133344-A1 | FULLERENE COMPOSITIONS | UNIVERSITEIT GENT (BE) | 2018-05-17 | — | — | US | disclosed |
| US-20170349852-A1 | THIOL-CARBOXYLIC ADDUCTS AS LUBRICATING ADDITIVES | THE LUBRIZOL CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9796700-B2 | ERK inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-10-24 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-05-18 | — | — | US | disclosed |
| US-9561228-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9504686-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-24 | — | — | US | disclosed |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137406-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885HPGD 1632/4885TSHR 3596/4885 |
| US-10029020-B2 | Fullerene compositions | NCL, PNN, ANXA3 | ALDH1A1 4558/4885HPGD 3351/4885TSHR 4546/4885 |
| US-20160002176-A1 | ERK INHIBITORS AND USES THEREOF | MAPK1, MAPK3, MAP4K2 | ALDH1A1 2289/4885HPGD 1071/4885TSHR 3598/4885 |
| US-20180133344-A1 | FULLERENE COMPOSITIONS | NCL, PNN, ANXA3 | ALDH1A1 4558/4885HPGD 3351/4885TSHR 4546/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885HPGD 1632/4885TSHR 3596/4885 |
| US-20160082008-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885HPGD 1632/4885TSHR 3596/4885 |
| US-20140228322-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | ALDH1A1 2838/4885HPGD 1632/4885TSHR 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.